The stock of Wave Life Sciences Ltd. (NASDAQ:WVE) increased by $0.13 on Wednesday to $5.46, up 2.44 percent. The last five days have seen an average of 481,162 shares of common stock traded. 1 time new highs were reached in the current year, with a fall of -$1.53. The average number of shares traded over the last 20 days was 251,455, while the average volume over the last 50 days totaled 228,214.
WVE stock appreciated 23.81% since last month. On 08/21/23, the company’s shares reached a one-month low of $4.21. The stock touched a high of $7.12 on 01/03/23, after rallying from a low of $3.04 in 52 weeks. The price of WVE stock has declined by -22.00% or -$1.53 this year, reaching a new high 1 time. Still, the stock price is down -23.31% from the 52-week high.
Insider Transactions
WVE stock investors should be aware that Wave Life Sciences Ltd. (WVE) stock had its last reported insider trading activity 28 days ago on Aug 23. On Aug 23, Chief Financial Officer Moran Kyle sold 37,062 shares at $4.75 each. This transaction resulted in the insider making $176,119. On Feb 16, BOLNO PAUL sold 29,400 shares at a price of US$4.04. After the transaction, the insider now owns 407,425 shares. Francis Chris had earlier sold 10,258 shares on Feb 16 for $4.03 a share. The transaction was completed for $41,340.
Financial Health
For the three months ended June 29, Wave Life Sciences Ltd.’s quick ratio was 1.30, while its current ratio was 1.30, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $166.37 million and revenue of $3.65 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. WVE’s return on assets (ROA) during the last 12 months has been -63.60%. There was a 362.30% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 385.80%.
Earnings Surprise
According to Wave Life Sciences Ltd.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $22.11 million, while revenues rose by 98.28% to $12.93 million. It was predicted that Wave Life Sciences Ltd.’s quarterly earnings would be -$0.2, but it ended up being -$0.33, beating the consensus by 39.40%. EBITDA was -$21.15 million for the quarter. At the end of Wave Life Sciences Ltd.’s most recent quarter ended June 29, its liabilities totaled 281.7 million, while its total debt was $35.16 million. Equity owned by shareholders amounts to $98.98 million.
Technical Picture
Here’s a quick look at Wave Life Sciences Ltd.’s (WVE) price momentum from a technical perspective. As of 19 September, the RSI 9-day stood at 67.92%, suggesting the stock is Neutral, with a 64.82% historical volatility rate.
The stochastic %K and %D were 76.83% and 77.16% respectively, while the average true range (ATR) was 0.37. Based on the 14-day stochastic reading of 91.11%, the RSI (14) reading is 65.10%. On the 9-day MACD Oscillator, the stock is at 0.19, and the 14-day reading is at 0.43.
Analyst Ratings
In its analyst report released on July 05, 2023, Raymond James began covering Wave Life Sciences Ltd. (NASDAQ: WVE). The stock was rated as an Outperform by the brokerage firm. Analysts have assigned Wave Life Sciences Ltd. (WVE) an Overweight rating. WVE is a stock that is recommended for selling by 0 brokerage firms, while 3 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 1 rate it overweight and 3 others recommend it as a buy.
What is WVE’s price target for the next 12 months?
The current consensus forecast for the stock is between $5.00 and $17.00, with a median target price of $7.00. In analyzing these forecasts, the average price target given by analysts for Wave Life Sciences Ltd. (WVE) is $8.21.
